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Animal venoms have evolved over millions of years for prey capture and defense from
predators and rivals. Snake venoms, in particular, have evolved a wide diversity of
peptides and proteins that induce harmful inflammatory and neurotoxic effects including
severe pain and paralysis, hemotoxic effects, such as hemorrhage and coagulopathy,
and cytotoxic/myotoxic effects, such as inflammation and necrosis. If untreated, many
envenomings result in death or severe morbidity in humans and, despite advances in
management, snakebite remains a major public health problem, particularly in developing
countries. Consequently, the World Health Organization recently recognized snakebite
as a neglected tropical disease that affects ∼2.7 million p.a. The major protein classes
found in snake venoms are phospholipases, metalloproteases, serine proteases, and
three-finger peptides. The mechanisms of action and pharmacological properties of
many snake venom toxins have been elucidated, revealing a complex multifunctional
cocktail that can act synergistically to rapidly immobilize prey and deter predators.
However, despite these advances many snake toxins remain to be structurally and
pharmacologically characterized. In this review, the multifunctional features of the
peptides and proteins found in snake venoms, as well as their evolutionary histories,
are discussed with the view to identifying novel modes of action and improving
snakebite treatments.
Keywords: snake venoms, multifunctional toxins, pathological mechanisms, evolution, snakebite treatment, pain,
hemotoxicity, myotoxicity
INTRODUCTION
The composition and evolutionary histories of animal venoms have fascinated the
scientific community for centuries. Venoms have evolved over millions of years to facilitate prey
capture and/or defense from predators and rivals. Snake venoms, in particular, likely originated in
the Cenozoic Era (Fry, 2005; Fry et al., 2006), and they are amongst the most well-characterized of
animal venoms, comprising a complex mixture of toxic, and pharmacologically-active proteins and
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peptides (Casewell et al., 2013; Chan et al., 2016). Tragically,
snake envenomation is a significant health and economic burden
worldwide. It is estimated 1.8–2.7 million snakebites and 81,410–
137,880 deaths occur annually worldwide (Kasturiratne et al.,
2008; Gutierrez et al., 2017), a problem which is mostly
associated with agricultural work, especially in South and
Southeast Asia, sub-Saharan Africa, and Central and South
America (Kasturiratne et al., 2008; Harrison et al., 2019). In
2017, the World Health Organization (WHO) finally recognized
the snakebite as a priority neglected tropical disease in which
morbidity andmortality affects mostly individuals under 30 years
old, who are often the most economically productive members of
a community (WHO, 2018).
Snake venoms have a distinct complexity when compared
to venoms from other animals such as spiders, scorpions,
and cone snails (Zelanis and Tashima, 2014). In these animal
venoms, the pharmacological effects are primarily caused by
disulfide bridged peptides, whilst snake venoms consist of a
more diverse array of larger proteins and peptides which results
in a wider variety of pharmacological and toxicological effects
(Zhang, 2015). These venoms comprise 50–200 components
distributed in dominant and secondary families which can be
presented in multiple proteins and peptides isoforms (Vonk
et al., 2011; Slagboom et al., 2017; Tasoulis and Isbister, 2017).
The dominant families are secreted phospholipases A2 (PLA2s),
snake venom metalloproteinases (SVMP), snake venom serine
proteases (SVSP), and three-finger peptides (3FTX), while the
secondary families comprise cysteine-rich secretory proteins, L-
amino acid oxidases, kunitz peptides, C-type lectins, disintegrins,
and natriuretic peptides (Slagboom et al., 2017; Tasoulis and
Isbister, 2017; Munawar et al., 2018). Interestingly, snake venom
composition varies interspecifically (Fry et al., 2008; Tasoulis and
Isbister, 2017), as well as intraspecifically, with many factors
influencing this diversity including age (Dias et al., 2013), gender
(Menezes et al., 2006; Zelanis et al., 2016), location (Durban et al.,
2011; Goncalves-Machado et al., 2016), diet (Barlow et al., 2009),
and season (Gubensek et al., 1974). This variability phenomenon
underpins toxin diversity and multifunctionality, and is of great
importance to be considered in antivenom production and
envenomation treatment (Gutierrez et al., 2017).
The pharmacological effects of snake venoms are classified
into three main types, hemotoxic, neurotoxic, and cytotoxic
(WHO, 2010). The major toxins involved in these effects
are the PLA2s, SVMPs, SVSPs, and 3FTXs, that alone or in
combination, are responsible for the multiple pharmacological
effects occurring in snakebite victims. For example, some PLA2s
and 3FTX are able to act on pre- or post-synaptic junctions
as antagonist of ion channels and nicotinic or muscarinic
receptors to induce severe neurotoxicity such as paralysis and
respiratory failure (Fry et al., 2003; Lynch, 2007; Casewell
et al., 2013; Harris and Scott-Davey, 2013; Tsetlin, 2015). In
addition, other PLA2s and 3FTXs, along with SVMPs, cause
local tissue damage resulting in swelling, blistering, bruising,
and necrosis, and systemic effects such as hypovolemic shock
(Gutierrez and Rucavado, 2000; Gutierrez et al., 2005; Harris
and Scott-Davey, 2013; Rivel et al., 2016). Furthermore, SVSPs
and SVMPs induce hemostatic and cardiovascular effects as
coagulopathy, hypotension and hemorrhage (Slagboom et al.,
2017). Interestingly, some PLA2s, SVSPs, and SVMPs are also
capable of triggering severe pain by modulating pain pathways
through activation of ion channels, such as transient receptor
potential vanilloid type 1 (TRPV1) and acid-sensing ion channel
(ASIC) (Bohlen et al., 2011; Zhang et al., 2017); and/or by pain
sensitization through inflammatory mediators (Zychar et al.,
2010; Menaldo et al., 2013; Ferraz et al., 2015; Mamede et al.,
2016; Zambelli et al., 2017b). The inflammation induced by the
elapid and viper venoms is widely reported to produce pain or
hyperalgesia in human and in experimental models (Hifumi et al.,
2015; Bucaretchi et al., 2016; Kleggetveit et al., 2016; Mamede
et al., 2016). Unfortunately, these are not completely reversed by
antivenom and anti-inflammatory therapies (Picolo et al., 2002;
Ferraz et al., 2015; Hifumi et al., 2015).
The toxicological effects induced by snakebite are currently
treated with intravenous administration of antivenom in
combination to analgesics, fluid therapy, hemodialysis and/or
antibiotics (Gutierrez et al., 2017). Although sufficient in
most cases, snakebite treatments have been challenged
by the continuous high numbers of clinical illness and
mortality associated with snakebites worldwide (WHO,
2018). Furthermore, chronic morbidity following snakebites
have been underestimated, with many victims reporting chronic
symptoms in the bitten region, including complex regional pain
syndrome (CRPA) (Seo et al., 2014; Kleggetveit et al., 2016) and
musculoskeletal disabilities (Jayawardana et al., 2016). Available
snakebite treatments face challenges associated with limited
para-specificity, poor antibody specificity, high incidences of
adverse reactions, low availability and poor affordability to
those who need them, along with poor efficacy against local
tissue effects (Williams et al., 2011; Gutierrez et al., 2017;
Ainsworth et al., 2018; Harrison et al., 2019). Therefore, current
research efforts are directed to the development of more effective
snakebite therapies able to generically fully inhibit the major
toxic components of snake venoms in order to better overcome
severe acute and chronic effects caused by snakebite.
In light of the public health importance and the
complexity of snake venoms, in this review we highlight
the multifunctionality, structure-activity relationships and
evolution of proteins and peptides in snake venoms. We aim
to provide a better understanding of their action mechanisms
and effects, and to bring attention to their undetermined
targets and a host of potential novel therapeutic targets
that might have implications for improving the treatments
of snakebites.
PHOSPHOLIPASES (PLA2s)
Phospholipases A2 play an important role in the neurotoxic
and myotoxic effects of snakebites (Harris and Scott-Davey,
2013). These proteins have molecular masses of 13–15 kDa
and are classified into groups I and II, which are found as
major components in the venoms of Elapidae and Viperidae,
respectively (Six and Dennis, 2000; Harris and Scott-Davey,
2013). In addition, a third group of PLA2s, termed IIE,
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have been predominately recovered from the venoms of non-
front fanged snakes, although their importance in the venom
arsenal remains unclear (Fry et al., 2012; Perry et al., 2018).
Studies reconstructing the evolutionary history of this multi-
locus gene family have demonstrated that each of these PLA2s
types (I, II, and IIE) have been independently recruited
into snake venom systems (Fry et al., 2012; Junqueira-De-
Azevedo et al., 2015), suggesting they have evolved their toxic
properties by convergent evolution (Lomonte and Rangel, 2012).
Although PLA2s from vipers and elapids share similar enzymatic
properties, both types have undergone extensive gene duplication
over evolutionary time, seemingly facilitating the evolution
of new toxic functions, and resulting in different patterns of
residue conservation (Lynch, 2007; Vonk et al., 2013; Dowell
et al., 2016; Figure 1A). In addition, the venoms of viper
snakes contain isoforms of group II PLA2s that are catalytically-
active (e.g., Asp49) and catalytically-less active (e.g., Lys49)
(Lomonte and Rangel, 2012).
A number of PLA2s exert strong myotoxic effects which
often lead to severe necrosis (Harris and Maltin, 1982;
Gutierrez and Ownby, 2003), and many of these toxins also
promote inflammation, including edema formation, cytokine
production and leukocyte recruitment, pain by inducing thermal
allodynia and mechanical hyperalgesia, paralysis through block
of neuromuscular transmission and intensify hemorrhage by
inhibiting coagulation (Table 1) (Camara et al., 2003; Chacur
et al., 2003; Camargo et al., 2008; Teixeira et al., 2011; Lomonte
and Rangel, 2012; Harris and Scott-Davey, 2013; Casais-E-Silva
et al., 2016; Costa et al., 2017; Zambelli et al., 2017b; Zhang
et al., 2017). Neurotoxic effects caused by these toxins, as
well as some of their proinflammatory effects, occurs via the
modulation of pre-synaptic terminals as well as sensory nerve-
endings (Camara et al., 2003; Harris and Scott-Davey, 2013;
Sribar et al., 2014; Zhang et al., 2017). The PLA2s pre-synaptic
effects are characteristic of β-neurotoxins and target the motor
nerve terminals at the neuromuscular junction (Sribar et al.,
2014; Gutierrez et al., 2017). The mechanisms in which certain
PLA2s exert their pre-synaptic effects are not fully understood,
and the primary targets remain unidentified, although the
PLA2 β-bungarotoxin is known to bind to K+ channels at
the pre-synaptic terminals via an accessory kunitz subunit
(Benishin, 1990; Sribar et al., 2014; Figure 1B). Overall, these pre-
synaptic effects induce robust exocytosis of the neurotransmitters
vesicles reserves which consequently lead to the depletion
of neurotransmitter release in the neuromuscular junction to
promote muscle paralysis (Harris et al., 2000; Sribar et al., 2014;
Gutierrez et al., 2017).
The inflammation induced by PLA2s has non-neurogenic
and neurogenic (substance-P dependent) components (Camara
et al., 2003; Camargo et al., 2008; Costa et al., 2017;
Zhang et al., 2017). The non-neurogenic component is mostly
caused by the hydrolysis of membrane lipids that generate
potent pro-inflammatory lipid mediators (Costa et al., 2017).
Additional non-neurogenic and neurogenic inflammations
induced by PLA2s use more complex mechanisms still not
fully understood. For example, leukocyte recruitment (De Castro
et al., 2000), mastocytes degranulation (Menaldo et al., 2017),
and macrophage activation (Triggiani et al., 2000; Granata
et al., 2006; Giannotti et al., 2013) were demonstrated to
occur independently of the generic PLA2s lipid hydrolysis
catalytic activity. Furthermore, substance-Pmediated neurogenic
inflammation has been described to be induced by PLA2s from
Crotalus durissus cascavella (Camara et al., 2003) and from Naja
mossambica (Camargo et al., 2008). Interestingly, the C-terminal
of Myotoxin-II (a Lys49-PLA2) isolated from Bothrops asper
was able to activate macrophages, showing this region maybe
be crucial for the observed enzymatic-independent inflammation
(Giannotti et al., 2013) (Figure 1A).
The pain induced by PLA2s is driven by inflammatory
processes and sensory neuronal activation. Bradykinin is an
important mediator of the inflammatory pain induced by
PLA2s (Moreira et al., 2014; Urs et al., 2014; Mamede
et al., 2016; Zambelli et al., 2017b). It induces mechanical
hyperalgesia dependent on the production of TNF-α, IL-1β, and
prostaglandins (Cunha et al., 1992). This suggests that PLA2s
contribute to an increase in arachidonic acid release from cell
membranes and its availability to be processed by cyclooxygenase
resulting in prostaglandin production (Verri et al., 2006).
Corroborating this hypothesis, studies performed in rodents
have demonstrated that PLA2s isolated from different snake
venoms induced hyperalgesia mediated by biogenic amines,
cytokines, prostaglandins, sympathomimetic amines, ATP, K+
release, purinergic receptor activation, and glial cell activation
(Nunez et al., 2001; Chacur et al., 2003, 2004; Zhang et al.,
2017). Interestingly, the presence of a strong catalytic activity
in the PLA2s is not essential for its nociceptive activity as
observed by the nociceptive effects of PLA2s “Lys49” variants
(Lomonte et al., 1994; Rong et al., 2016; Zhang et al., 2017). Direct
activation of sensory neurons was demonstrated by MitTx from
Micrurus tener tener, a heteromeric complex between a PLA2
and a kunitz peptide (Bohlen et al., 2011), and by the Lys49
PLA2 BomoTx from the Brazilian viper Bothrops moojeni (Zhang
et al., 2017). MitTx activates somatosensory neurons and was
found to be a potent and selective agonist of ASIC channels
(Figure 1C). This agonistic effect induces robust pain behavior
in mice via activation of ASIC1 channels on capsaicin-sensitive
nerve fibers (Bohlen et al., 2011). BomoTx also activated a cohort
of sensory neurons to induce ATP release followed by activation
of purinergic receptors (Zhang et al., 2017). Unfortunately, the
primary target of this neuronal activation is still unknown.
This same toxin induced non-neurogenic inflammatory pain,
thermal hyperalgesia dependent on TRPV1 channels-expressing
nerve fibers, andmechanical allodynia dependent on P2X2/P2X3-
expressing fibers (Zhang et al., 2017).
The multifunctionality of PLA2s is evidenced by their
myotoxic, neurotoxic and enzymatic functions, as well as by their
inflammatory properties. There is evidence that separate domains
and regions of the PLA2s structure participate in these various
activities (Figures 1A,B). For example, for the Lys49-PLA2 from
Bothrops asper and Agkistrodon piscivorus piscivorus, the C-
terminal region of these toxins (residues 115–129) were identified
as the active sites responsible for their myotoxic effects (Lomonte
et al., 1994; Nunez et al., 2001) (Figure 1A). Interestingly, the
same C-terminal region in BpirPLA2-I isolated from Bothrops
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FIGURE 1 | Structure of PLA2s from snake venoms. (A) Alignment of the primary structure of PLA2s from snakes belong to Elapidae (Class I) and Viparinae (Class II).
β-Bungarotoxin (β-BTX) from Bungarus multicinctus (Class I, Basic) (Uniprot P00617), OS2 from Oxyuranus scutellatus (Class I, Basic) (Uniprot Q45Z47), Myotoxin II
from Bothrops asper (Class II, Basic) (Uniprot P24605), APP-D49 from A. piscivorus (Class II, Basic) (Uniprot P51972), BpirPLA2-I from Bothrops pirajai (Class II, Acid)
(Uniprot C9DPL5), Bothropstoxin-1 (BThTx-I) from Bothrops jararacussu (Class II, Basic) (Uniprot Q90249), and Crotoxin B from Crotalus durissus terrificus (Class II,
Basic) (Uniprot P24027). Green: N-terminal region critical for enzymatic and neurotoxic properties, C-terminal region essential for enzymatic activity and central
Histidine in the catalytic site (Rouault et al., 2006), Yellow: C-terminal region with myotoxic properties (Lomonte et al., 1994; Nunez et al., 2001), Dark green: C-terminal
region with anti-platelet aggregation activity (Teixeira et al., 2011), Gray: Lysin residues involved in the nociceptive, and/or endematogenic properties (Zambelli et al.,
2017a) and Cyan: modified residues in the Crotoxin B which lead to alterations in the enzymatic, toxic, and pharmacological properties (Soares et al., 2001). (B–E)
Cartoon representation of the three-dimensional structure of (B) β-Bungarotoxin with the PLA2 domain in red and knutiz domain in green (PDB 1BUN), (C) MitTx1 and
ASIC1a channel complex with PLA2 domain in red, knutiz domain in green and ASIC1a channel in blue (PDB 4NTY), (D) Crotoxin B (PDB 2QOG) and (E) BThrTx1
(PDB 3HZD). (D,E) Highlighted in blue are the amino acids positions involved in the enzymatic, toxic and pharmacological properties of Crotoxin B (Soares et al., 2001)
and in the nociceptive and/or endematogenic properties in BThrTx1 (Zambelli et al., 2017a). The central histidine in the catalytic site of Crotoxin B is highlighted in red.
pirajai had anticoagulant activity through inhibition of platelet
aggregation (Teixeira et al., 2011). Crotoxin B, an Asp49-PLA2,
and a major component of the venom of Crotalus durissus
terrificus, has toxic active sites fully independent of its enzymatic
activity (Soares et al., 2001; Figure 1D), while Lemnitoxin, a
basic class I PLA2 isolated fromMicrurus lemniscatus, has strong
myotoxic and proinflammatory effects but no neurotoxic activity
(Casais-E-Silva et al., 2016). A detailed mutational study using
the PLA2 OS2 from the Australian Taipan snake Oxyuranus
scutellatus scutellatus revealed that a 500-fold loss in enzymatic
activity had only a minor effect on its neurotoxicity (Rouault
et al., 2006). Furthermore, the enzymatic activity of OS2 was
dependent of the N- and C-terminal regions, and the N-
terminal region had a major role in the central nervous system
Frontiers in Ecology and Evolution | www.frontiersin.org 4 June 2019 | Volume 7 | Article 218
Ferraz et al. Multifunctional Toxins From Snakes
neurotoxicity. An alanine scan of the Lys49-PLA2 from Bothrops
jararacussu (BThTx-I) demonstrated distinct regions involved in
the hyperalgesia and edema (Zambelli et al., 2017a). In this study,
the mutant Arg118Ala lost both nociceptive and edematogenic
properties, Lys115Ala and Lys116Ala lost the nociceptive effects
without interfering with the edema formation and Lys122Ala
lost the nociceptive properties and had weak inflammatory
effects (Figure 1E). Similarly, an independent study showed the
Lys122Ala substitution led to reduced membrane damaging and
myotoxic activities (Ward et al., 2002). This C-terminal region is
characterized by the presence of basic and hydrophobic residues
which have been strongly associated with the ability of PLA2s
to interact and penetrate the lipid bilayer (Delatorre et al., 2011;
Gutierrez and Lomonte, 2013).
The variability of PLA2 isoforms observed in the venom of
different snakes may reflect a variety of factors, including
the evolutionary history, phylogeography, diet, and/or
environmental conditions relating to a species or populations
within a species (Zancolli et al., 2019). Many snake venom toxins
are known to be encoded by multi-locus gene families (Casewell
et al., 2013), and the resulting genes within those families have
been found clustered together in arrays on microchromosomes,
likely as the result of tandem gene duplication events (Vonk
et al., 2013). The process of gene duplication and loss underpins
the evolution of many snake venom toxin families, including
the PLA2s (Lynch, 2007; Vonk et al., 2013; Casewell et al.,
2014; Dowell et al., 2016), with duplications likely initially
stimulating a gene dosing effect while also freeing duplicates
from evolutionary constraints, and thus enabling a scenario
that may facilitate protein sub- and/or neo-functionalization
(Lynch and Conery, 2000). Indeed, studies have demonstrated
that extremely divergent venom phenotypes (e.g., neurotoxic vs.
haemorrhagic) observed within populations of the same snake
species, or between closely related species, are at least partially
the result of major genomic differences in PLA2 toxin loci, with
variation at different gene complexes resulting in markedly
different haplotypes (Dowell et al., 2018; Zancolli et al., 2019). It
remains unclear as to the specific processes that underpin such
diversity, although natural selection driven by environmental
factors and hybridization events have both been proposed
(Dowell et al., 2018).
SNAKE VENOM METALLOPROTEINASES
(SVMPs)
Snake Venom MetalloProteinases (SVMPs) are zinc-dependent
proteinases ranging from 20 to 110 kDa in size and are
categorized into P-I, P-II, and P-III classes according to their
structural domains (Hite et al., 1994; Jia et al., 1996; Fox and
Serrano, 2005) (Figure 2). These toxins are major components of
viper venoms and play a key role in the toxicity of these snake
venoms (Table 1; Tasoulis and Isbister, 2017). Venom SVMPs
have evolved from ADAM (a disintegrin and metalloproteinase)
proteins, specifically ADAM28 (Casewell, 2012), with the P-
III being the most basal structural variant consisting of
metalloproteinase, disintegrin-like, and cysteine-rich domains
(Moura-Da-Silva et al., 1996; Casewell et al., 2011; Figure 2B).
Subsequently, P-II SVMPs diverged from P-IIIs and consist
of a metalloproteinase and disintegrin domain, with the latter
typically detected in venom as a proteolytically processed product
(Fox and Serrano, 2008; Casewell et al., 2011). The final class, P-
I SVMPs which consist only of the metalloproteinase domain,
appeared to have evolved on multiple independent occasions
in specific lineages as a result of loss of the P-II disintegrin-
encoding domain (Casewell et al., 2011). Throughout this diverse
evolutionary history, SVMPs show evidence of extensive gene
duplication events, coupled with bursts of accelerated molecular
evolution (Casewell et al., 2011; Vonk et al., 2013). However,
while all three classes of SVMPs have been described from
viper venoms, only P-III SVMPs have been detected in elapid
and “colubrid” venoms (Casewell et al., 2015). While these
P-III SVMPs are typically relatively lowly abundant venom
components in elapid snakes (e.g., <10% of venom toxins),
they can be major components in “colubrids” (Mackessy and
Saviola, 2016; Pla et al., 2017; Tasoulis and Isbister, 2017; Modahl
et al., 2018a). These abundance differences likely underpin
the distinct pathologies observed following envenomings by
snakes found in these families. SVMPs contribute extensively to
the hemorrhagic and coagulopathic venom activities following
bites by viperid snakes, and the diversity of SVMPs isoforms
often present in their venom likely facilitate synergistic effects,
such as simultaneous action on multiple steps of the blood
clotting cascade (Kini and Koh, 2016; Slagboom et al., 2017).
Certain “colubrid” snakes, whether medically important or
not, also show evidence of having multiple SVMP toxins in
their venom, even if they do not show the sub-class diversity
observed in the vipers (Mackessy and Saviola, 2016; Pla et al.,
2017; Modahl et al., 2018a; Perry et al., 2018). However, it is
relatively uncommon for elapid snakebites to cause systemic
hemotoxicity (Slagboom et al., 2017) and this is likely a
consequence of those venoms exhibiting little diversity or
abundance of SVMPs, and instead usually being dominated
by neurotoxic toxin families such as the 3FTXs and PLA2s
(Tasoulis and Isbister, 2017).
As mentioned above, the SVMPs are known for their
hemorrhagic activity as well as for their ability to influence
multiple steps of the blood clotting cascade, resulting in a lethal
combination of systemic hemorrhage and incoagulable blood in
prey and/or victims (Markland and Swenson, 2013). Research
has revealed that the effects of SVMP-induced hemorrhage
relies on a mechanism that occurs in two steps (Gutierrez et al.,
2005; Escalante et al., 2011). First, SVMPs cleave the basement
membrane and adhesion proteins of endothelial cells-matrix
complex to weaken the capillary vessels. During the second
stage, the endothelial cells detach from the basement membrane
and become extremely thin, resulting in disruption of the
capillary walls and effusion of blood from the fragile capillary
walls. In addition to the proteinase activity, SVMPs impact
on homeostasis by altering coagulation, which contributes
to their toxic hemorrhagic effects (Markland, 1998; Takeda
et al., 2012; Slagboom et al., 2017). This occurs through
modulation of factors such as fibrinogenase and fibrolase that
mediate the coagulation cascade, depletion of pro-coagulation
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TABLE 1 | Snake toxins and their multifunctional roles in the toxicity induced by snakebites.
Toxin group Pain Inflammation Hemorrhage and coagulopathy Necrosis Paralysis
PLA2s Acute pain through ASIC1
activation (Bohlen et al., 2011)
Inflammatory pain, thermal
hypersalgesia and mechanical
allodynia (Zhang et al., 2017)
Excitation of sensory neurons
(Bohlen et al., 2011; Zhang et al.,
2017)
Neurogenic inflammation
(Camara et al., 2003; Camargo
et al., 2008)
Non-neurogenic inflammation
(Costa et al., 2017)
Endematogenic and
pro-inflammatory (Camara et al.,
2003; Casais-E-Silva et al.,
2016; Costa et al., 2017)
Inhibits platelet aggregation
(Teixeira et al., 2011)
Phospholipase activity
(Gutierrez and Ownby, 2003)
Myotoxic (Harris and Maltin,
1982)
Pre-synaptic toxin, block of
neuromuscular transmission
leading to muscle paralysis (Sribar
et al., 2014; Gutierrez et al., 2017)
SVMP Inflammatory hyperalgesia
(Fernandes et al., 2007;
Bernardes et al., 2015; De Toni
et al., 2015; Ferraz et al., 2015)
Endematogenic activity
independent of pro-inflammatory
mediators (Laing et al., 2003)
Cleavage of basement membrane
of capillary vessels and endothelial
cells adhesion proteins (Gutierrez
et al., 2005; Escalante et al., 2011)
Procoagulant through activation of
prothrombin and Factor X (Takeda
et al., 2012; Ainsworth et al., 2018)
Inhibition of platelet aggregation
(Kamiguti, 2005)
Dermonecrotic activity
dependent on TNF signaling
(Laing et al., 2003)
Potential paralysis through
inhibition of α-7 neuronal AChR
by the cysteine-rich and
disintregin-like domains complex
(Brust et al., 2013)
SVSP Mild mechanical hyperalgesia
(Menaldo et al., 2013)
Leucocyte migration (Menaldo
et al., 2013)
Mild edema (Zychar et al., 2010)
Procoagulant through activation of
prothrombin and factors VII and X
(Kini, 2005)
Anti-coagulant through activation
of Protein C and thrombin-like
enzymatic activity
(Kini, 2006; Serrano, 2013)
Not described Not described
3FTX Analgesic effect through
inhibition of ASIC channels
(Diochot et al., 2012).
Not described Inhibits platelet aggregation (Girish
and Kini, 2016)
Inhibits Factor X (McDowell et al.,
1992)
Cytotoxins induce necrosis in
skeletal muscle (Ownby et al.,
1993).
Pre- and post-synaptic toxin,
block of neuromuscular
transmission through modulation
of nAChR, AChE, NaV1.4, and
L-type calcium channels (Grant
and Chiappinelli, 1985;
Changeux, 1990; De Weille et al.,
1991; Garcia et al., 2001;
Marquer et al., 2011; Yang et al.,
2016)
Their functional properties associated to pain, inflammation, hemorrhage, necrosis and paralysis are described.
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FIGURE 2 | Structure of metalloproteinaises from snake venoms. (A) Alignment of the primary structure of the SVMPs Jararhagin from Bothrops jararaca (Uniprot
P30431) and VAPB2 from Crotalus atrox (Uniprot Q90282) belonging to the class P-III, BlatH1 from Bothriechis lateralis (Uniprot U5PZ28) belonging to the class P-II,
and Ba-PI from Bothrops asper (Uniprot P83512) and Adamalysin from Crotalus adamanteus (Uniprot P34179) belonging to classes P-I. Cysteines are colored in red,
the disintegrin-like domain is highlighted in green and the cysteine-rich domain is highlighted in blue. (B) Cartoon representation of the three-dimensional structure of
the class P-III metalloproteinase VAPB2 from Crotalus atrox (PDB 2DW0). The metalloproteinase domain is colored in orange, the disintegrin-like domain (D-like) is
colored in green and the cysteine-rich domain (Cys-rich) is colored in blue. The disulphide bridges are colored in yellow.
factors through consumption processes (e.g., Factor X,
prothrombin and fibrinogen), platelet aggregation inhibition
and inflammatory activities (Kamiguti, 2005; Kini, 2005;
Takeda et al., 2012; Kini and Koh, 2016; Slagboom et al., 2017;
Ainsworth et al., 2018).
Some SVMPs also induce inflammation, including edema,
and pain by triggering hyperalgesia (Dale et al., 2004; da
Silva et al., 2012; Bernardes et al., 2015). The inflammation
induced by jararhagin, a class P-IIIb metalloproteinase with
potent hemorrhagic and dermonecrotic activity isolated from
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Bothrops jararaca, produced TNF-α and IL-1β in vivo (Laing
et al., 2003; Clissa et al., 2006), while BJ-PI2, isolated from the
same snake species, lacked hemorrhagic and necrotic activities
but still induced vascular permeability and inflammatory cell
migration (da Silva et al., 2012). Curiously, the edema formation
induced by jararhagin was independent of pro-inflammatory
mediators such as TNF, IL-1β, and IL-6 (Laing et al., 2003).
Neurogenic inflammation was also implicated in the local
hemorrhage induced by Bothrops jararaca which was shown
to be dependent on serotonin and other neuronal factors
(Goncalves and Mariano, 2000). The mechanisms on how
neurogenic inflammation is triggered by the snake venom
components and how it participates in the hemorrhagic process
are still not understood. Pain induced by SVMPs is characterized
by hyperalgesia and inflammatory pain, which is dependent
on the production of cytokines, nitric oxide, prostaglandins,
histamine, leukotrienes, and migration of leukocytes, mast cell
degranulation and NFkB activation (Fernandes et al., 2007;
Bernardes et al., 2015; De Toni et al., 2015; Ferraz et al., 2015).
However, the mechanisms underlying SVMP-induced pain
are still poorly understood, with neurogenic inflammation
and neuronal excitatory properties still underexplored. The
research reported to date indicates that SVMPs induce
the production of inflammatory mediators and activate
cytokine/chemokine cascades and the release of prostaglandins
and sympathetic amines to engender nociceptor sensitization
(Verri et al., 2006; De Toni et al., 2015; Ferraz et al., 2015).
The multifunctional properties of SMVPs are also well-
described. Class P-III SVMPs tend to display stronger
hemorrhagic activity compared to P-I and P-II SVMPs, possibly
due to the disintegrin-like and cysteine-rich domains enabling
binding to relevant targets in the extracellular matrix of capillary
vessels. The functions of these domains have been investigated
in inflammation, revealing that these domains are sufficient
to induce pro-inflammatory responses through production
of TNF-α, IL-1β and IL-6, and leukocyte migration, in which
mechanisms and primary targets are still unknown (Clissa et al.,
2006; Ferreira et al., 2018). These observations suggest that these
domains are involved in the inflammatory hyperalgesia induced
by SVMPs. Furthermore, the pronounced hemorrhagic and
necrotic activities are strongly dependent on biological effects
driven by the disintegrin-like and cysteine-rich domains, as
observed for BJ-PI2 (da Silva et al., 2012). The hemorrhagic
activity of Bothrops jararaca venom was also shown dependent
on neurogenic inflammation (Goncalves and Mariano, 2000).
These findings implicate the disintegrin-like and/or cysteine-rich
domains as key player(s) in these neurogenic mechanisms, and
possibly in non-inflammatory pain, from which the neuronal
targets are still to be identified.
SNAKE VENOM SERINE PROTEINASES
(SVSPs)
Snake Venom Serine Proteinases (SVSPs) belong to the S1
family of serine proteinases and display molecular masses
ranging from 26 to 67 kDa and two distinct structural domains
(Figure 3). These venom toxins have evolved from kallikrein-
like serine proteases and, following their recruitment for use
in the venom gland, have undergone gene duplication events
giving rise to multiple isoforms (Fry et al., 2008; Vaiyapuri
et al., 2012). SVSPs catalyze the cleavage of polypeptide chains
on the C-terminal side of positively charged or hydrophobic
amino acid residues (Page and Di Cera, 2008; Serrano,
2013). Similar to SVMPs, SVSPs have been described in the
venom of a wide variety of snake families, although they
are typically only abundant in viper venoms, and much less
common in the venoms of elapid and “colubrid” snakes
(Tasoulis and Isbister, 2017; Modahl et al., 2018a). Whilst the
SVMPs are well-known for their ability to rupture capillary
vessels, SVSPs execute their primary toxicity by altering
the hemostatic system of their victims, and by inducing
edema and hyperalgesia through mechanisms still poorly
understood (Table 1). Hemotoxic effects caused by SVSPs
include perturbations of blood coagulation (pro-coagulant or
anti-coagulant), fibrinolysis, platelet aggregation and blood
pressure, with potential deadly consequences for snakebite
victims (Murakami and Arni, 2005; Kang et al., 2011; Serrano,
2013; Slagboom et al., 2017).
Pro-coagulant SVSPs have been described to activate multiple
coagulation factors, including prothrombin and factors V, VII,
and X (Kini, 2005; Serrano, 2013). For example, the activation
of prothrombin produces thrombin which in turn produces
fibrin polymers that are cross-linked. Thrombin also activates
aggregation of platelets which, together with the formation
of fibrin clots, results in coagulation (Murakami and Arni,
2005). In addition, platelet-aggregating SVSPs will activate the
platelet-receptors to promote binding to fibrinogen and clot
formation (Yip et al., 2005). These procoagulant and platelet-
aggregating activities will lead to the rapid consumption of
key factors in the coagulation cascade and clot formation.
On the other hand, anticoagulant SVSPs effects involve the
activation of Protein C, which subsequently inactivates the
coagulant factors Va and VIIIa (Kini, 2006). Furthermore,
fibrinolytic SVSPs play an important role in the elimination of
blood clots by acting as thrombin-like enzymes or plasminogen
activators, which eliminates the fibrin in the clots and contributes
significantly to the establishment of the coagulopathy (Kang
et al., 2011; Serrano, 2013). Through the activation/depletion and
inactivation of these coagulation factors, the clotting of blood
is prevented, leading to uncoagulable blood, and external and
internal bleeding.
Little is known about inflammatory responses and
hyperalgesia induced by SVSPs. Studies suggest SVMPs
and PLA2s have a pivotal role in the inflammatory
responses and pain induced by snake venoms, while
SVSPs have an important role in inflammation and a
minor role in pain (Zychar et al., 2010; Menaldo et al.,
2013). SVSPs in the venoms of Bothrops jararaca and
Bothrops pirajai induce inflammation through edema
formation, leucocyte migration (mainly neutrophils)
and mild mechanical hyperalgesia, however, the
mediators involved in these effects are still unknown
(Zychar et al., 2010; Menaldo et al., 2013).
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FIGURE 3 | Structure of Serine proteinases from snake venoms. (A) Alignment of the primary structure of the SVSPs Dav-PA from Deinagkistrodon acutus (Uniprot
Q9I8X1), BPA from Bothrops jararaca (Uniprot Q9PTU8), and ACC-C from Agkistrodon contortrix (Uniprot P09872). In Dav-PA, the N- and C-terminal domains are
highlighted in blue and green, respectively. (B) Cartoon representation of the three-dimensional structure of the SVSP Dav-PA from Deinagkistrodon acutus (PDB
1OP0), with N- and C-terminal domains colored in blue and green, respectively.
THREE-FINGER TOXINS (3FTXs)
Three-fingers toxins (3FTXs) are non-enzymatic neurotoxins
ranging from 58 to 81 residues that contain a three-finger
fold structure stabilized by disulfide bridges (Osipov and
Utki, 2015; Kessler et al., 2017; Figure 4A). They are present
mostly in the venoms of elapid and colubrid snakes, and
exert their neurotoxic effects by binding postsynaptically at the
neuromuscular junctions to induce flaccid paralysis in snakebite
victims (Barber et al., 2013). Three-finger toxins differ in length,
with short-chain 3FTXs including α-neurotoxins, β-cardiotoxins,
cytotoxins, fasciculins and mambalgins, which comprise of 57–
62 residues and 4 disulfide bridges, and long-chain 3FTXs which
include α-neurotoxins and γ-neurotoxins, hannalgesin and κ-
neurotoxins, and comprise 66–74 residues and five disulfide
bridges. Furthermore, they can exist as monomers and as
covalent or non-covalent homo or heterodimers. The diversity
of 3FTX isoforms described above are a direct result of a
diverse evolutionary history, whereby ancestral 3FTXs have
diversified by frequent gene duplication and accelerated rates
of molecular evolution. These processes, which are broadly
similar to those underpinning the evolution of the other toxin
families described above, are particularly associated with the
evolution of a high-pressure hollow-fanged venom delivery
system observed in elapid snakes (Sunagar et al., 2013).
For example, gene duplication events have resulted in the
expansion of 3FTX loci from one in non-venomous snakes
like pythons, to 19 in the elapid Ophiophagus hannah (king
cobra) (Vonk et al., 2013), and selection appears to have
acted extensively on surface exposed amino acid residues in
these resulting paralogous elapid 3FTX genes (Sunagar et al.,
2013). The consequences of this evolutionary history are the
differential production of numerous 3FTX isoforms that often
exhibit considerable structural differences and distinct biological
functions (Figures 4B–E). Although many elapid snakes exhibit
broad diversity of these functionally varied toxins in their venom
(e.g., multiple short- and long-chain 3FTX isoforms), it remains
unclear why particular functional variants are enriched in the
venoms of certain elapid lineages, such as the cytotoxin-rich
venoms of cobras (genus Naja) or the neurotoxin-rich venoms
of mambas (genus Dendroaspis) (Tan et al., 2015; Lauridsen
et al., 2017; Ainsworth et al., 2018). However, evidence of
taxon-specific 3FTXs in the venoms of certain “colubrid” snakes
(Pawlak et al., 2006; Mackessy and Saviola, 2016; Modahl et al.,
2018a), coupled with pseudogenization of 3FTXs in species that
no longer rely on their venom (Li et al., 2005), suggests that
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FIGURE 4 | Structure of three-finger toxins from snake venoms. (A) Alignment of the primary structure of α-cobratoxin from Naja kaouthia (Uniprot P01391),
α-bungarotoxin from Bungarus multicinctus (Uniprot P60615), fasciculin from Dendroaspis angusticeps (Uniprot P0C1Y9), Calciseptin from Dendroaspis polylepis
polylepis (Uniprot P22947), mambin from Dendroaspis jamesoni kaimosae (Uniprot P28375), mambalgin-1 from Dendroaspis polylepis polylepis (Uniprot P0DKR6),
cytotoxin 1 from Naja atra (Uniprot P60304), and calliotoxin from Calliophis bivirgatus (Uniprot P0DL82). (B–E) Cartoon representation of the three-dimensional
structure of the 3FTXs short-chain mambalgin-1 from Dendroaspis polylepis polylepis (PDB 5DU1) (B), long-chain α-bungarotoxin from Bungarus multicinctus (PDB
1ABT) (C), non-covalent homodimer α-cobratoxin from Naja kaouthia (PDB 4AEA) (D), and covalent heterodimer irditoxin from Boiga irregularis (PDB 2H7Z) (E). (F)
Cartoon representation of the three-dimensional structure of Fascilulin-2 bound to the AChE (PDB 4BDT). The residues Arg24, Lys25, Pro31 and Leu35 which form
hydrogen bonds with AChE are shown in orange. (G–J) Cartoon representation of the three-dimensional structure of the muscarinotoxin 1 (MT1, PDB 4DO8) (G) and
muscarinotoxin 7 (MT7, PDB 2VLW) (H), and respective analogs displaying the modified loop 1 (PDB 3FEV) (I) and loop 3 (PDB 3NEQ) (J) in light orange color. (K)
Neurotoxin II from N. oxiana (PDB 1NOR). The residues Ser29, His31, Gly33 and Thr34 which form hydrogen bonds with the α-subunit of nAChR are shown in
orange, and the residue Arg32 forming ionic interactions with the α-subunit of nAChR is shown in yellow. (L) Neurotoxin b (NTb) from O. Hannah (PDB 1TXA). The
residues Lys24, Trp26, and Asp28 that form hydrogen bonds with the α-subunit nAChR are shown in orange.
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selection for prey capture may be at least partially responsible for
influencing differential 3FTX representation.
Despite the shared three-finger fold, the 3FTXs have
diverse targets and biological activities. For example, α-
neurotoxins inhibit muscle acetylcholine receptors (nAChR)
(Changeux, 1990), κ-neurotoxins inhibits neuronal AChR
(Grant and Chiappinelli, 1985), muscarinic toxins inhibit
muscarinic receptors (Marquer et al., 2011), fasciculins inhibit
acetylcholinesterase (AChE) (Marchot et al., 1998), calciseptine
modulates L-type calcium channels (De Weille et al., 1991;
Garcia et al., 2001), cardiotoxins interact non-specifically
with phospholipids (Konshina et al., 2017), or induce insulin
secretion (Nguyen et al., 2012), mambin interacts with platelet
receptors (McDowell et al., 1992), exactin inhibits Factor X
(Girish and Kini, 2016), β-cardiotoxins inhibit β-adrenoreceptors
(Rajagopalan et al., 2007), MTα inhibits α-adrenoreceptors
(Koivula et al., 2010), mambalgins inhibit ASIC channels
(Diochot et al., 2012), Tx7335 that activates potassium channels
(Rivera-Torres et al., 2016) and calliotoxin activates voltage-
gated sodium channels (NaV) (Yang et al., 2016). Their toxic
biological effects include flaccid or spastic paralysis due to the
inhibition of AChE and ACh receptors (Grant and Chiappinelli,
1985; Changeux, 1990; Marchot et al., 1998; Marquer et al.,
2011), and activation of NaV1.4 (Yang et al., 2016) and L-type
calcium channels (Garcia et al., 2001) in the periphery, necrosis
through the action of cardiotoxins (cytotoxins) (Konshina et al.,
2017), alteration of the cardiac rate through modulation of α-
and β-adrenoreceptors (Rajagopalan et al., 2007; Koivula et al.,
2010), and altered homeostasis through inhibition of platelet
aggregation (McDowell et al., 1992) and Factor X (Girish and
Kini, 2016). In addition to theirmultitude of bio-activities, 3FTXs
can remarkably display toxicities that target distinct classes of
organisms as demonstrated in non-front fanged snake venoms
that produce 3FTX isoforms which are non-toxic to mice but
highly toxic to lizards, and vice-versa (Modahl et al., 2018b).
Some 3FTXs are able to induce analgesia through inhibition
of ASIC channels (Salinas et al., 2014), while no 3FTXs are
known to be involved in inflammation and hyperalgesia as
commonly reported for other snake toxins. Furthermore, 3FTXs
are relatively small compared to the other snake toxins discussed
herein, and do not exhibit multiple domains to produce their
multiple toxic functions. Nevertheless, the number of receptors,
ion channels, and enzymes targeted by snake 3FTXs highlights
the unique capacity of this fold to modulate diverse biological
functions and the arsenal of toxic effects that are induced by
3FTXs. The uniquemultifunctionality of the 3FTX scafold occurs
because of their resistance to degradation and tolerance to
mutations and large deletions (Kini and Doley, 2010). Therefore,
the structure-activity relationship of the 3FTXs is complex and
yet to be fully understood. Their functional sites are located on
various segments of the molecule surface. Conserved regions
determine structural integrity and correct folding of 3FTXs to
form the three loops, including eight conserved cysteine residues
found in the core region. Aromatic residues (Tyr25 or Phe27)
are conserved in most 3FTXs and essential to their folding.
Another conserved features are the antiparallel β-sheet structure
and charged amino acid residues also essential to stabilize the
native conformation of the protein by forming hydrogen and
ionic interactions, respectively (Torres et al., 2001). Additional
disulfide bonds can be observed either in the loop I or loop
II which can potentially change the activity of the 3FTX in
some cases.
Specific amino acid residues in critical segments of the 3FTXs
have been identified to be important for binding to their targets.
For example, the interactions between fasciculin and AChE
enzyme has been studied. The first loop or finger of fasciculin
reaches down the outer surface of the enzyme, while the second
loop inserts into the active site and exhibit hydrogen bonds and
hydrophobic interaction (Harel et al., 1995; Figure 4F). Several
basic residues in fasciculin make key contacts with AChE. From
docking studies, hydrogen bonds, and hydrophobic interactions
where shown to establish receptor-toxin assembly. Six amino
acid residues (Lys25, Arg24, Asn47, Pro31, Leu35 and Ala12) of
fasciculin interact with the AChE residues by forming hydrogen
bonds at its active site. Hydrophobic interactions are also
observed between eight amino acid residues (Lys32, Cys59, Val34,
Leu48, Ser26, Gly36, Thr15, Asn20) from fasciculin and the
enzyme active site (Waqar and Batool, 2015). These interactions
involve charged residues but lacks intermolecular salt linkages.
Muscarinic toxins from mamba venoms, such as MT1 and
MT7 (Figures 4G,H), act as highly potent and selective
antagonists of M1 receptor subtype through allosteric
interactions with the M1 receptor. Fruchart-Gaillard et al.
(2012) synthesized seven chimeric 3FTXs based on MT1 and
MT7 proteins that have remarkable affinity for α1A-adrenoceptor
receptor subtypes but low affinity for M1 receptor. In this study,
substitution within loop 1 and loop 3 weaken the toxin
interactions with the M1 receptor, resulting in a 2-fold decrease
in affinity (Figures 4I,J). Furthermore, modifications in loop
2 of the MT1 and MT7 significantly reduce the affinity for the
M1 receptor. Interestingly, a significant increase in affinity was
achieved on the α1A-adrenoceptor by combined modifications
in loops 1 and 3, where loop 1 forms a critical interaction with
the receptor (Fruchart-Gaillard et al., 2012). Another muscarinic
toxin named MTβ was designed based on ρ-Da1a protein from
Black Mamba which is known to have affinity for the muscarinic
receptor. The Ser/Ile38 and Ala/Val43 substitutions in ρ-Da1a
could be responsible for the increased affinity of MTβ for α1B-
adrenoreceptor and α1D-adrenoreceptor (Blanchet et al., 2013).
These two residues were not located at the tip of the toxin loop,
however, they played a critical role in the interactions with their
molecular targets (Bourne et al., 2005). These mutations seem to
induce a significant change in the structure of the toxin which is
mostly due to additional hydrophobic interactions between Ile38
and the aliphatic side chains of the toxin that may induce a slight
movement of the side chain surrounding Ser/Ile38.
Neurotoxin II (NTII) from Naja oxiana is a potent blocker
of nAChR. NTII is a short chain α-neurotoxin which consists of
61 amino acid residues and four disulfide bridges (Figure 4K). A
computationalmodel for examining the interactions of NTII with
the Torpedo californica nAChR has been studied (Mordvintsev
et al., 2005). The model showed that the binding of the short
α-neurotoxin occurs by rearranging the aromatic residues in
the binding pocket. The insertion of the loop II into the
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binding pocket of a nAChR induces the neurotoxin activity and
significantly determines the toxin-receptor interactions, while
loop I and III contact the receptor residues by their tips only and
determine the immunogenicity of the short neurotoxins. In the
model, the Arg32 NTII residue forms an ionic pair with Trp149
from the nAChR and is observed as the strongest interaction.
Hydrogen bond interactions such as Asp30 from loop II with
Tyr198 of the nAChR and Lys46 from loop III with Thr191 of
the nAChR complement the ionic interaction between NTII and
its target receptor. Aside from hydrogen bonds, van-der-Waals
interactions were also observed at the fingertip of loop II amino
acid residues (Lys25, Trp27, Trp28, Ser29, His31, Gly33, Thr34
and Arg38) (Mordvintsev et al., 2005).
The structure of neurotoxin b (NTb), a long neurotoxin
from Ophiophagus hannah, has been elucidated (Peng et al.,
1997; Figure 4L). Conserved residues in loop II also play an
important role in the toxicity of the long neurotoxins by making
ionic interactions between toxin and receptor. Positively charged
residues Trp27, Lys24 and Asp28 are highly conserved residues
in the long neurotoxins. Furthermore, a modification of the
Trp27 in the long neurotoxin analog of NTb from king cobra
venom led to a significant loss in neurotoxicity. The additional
disulphide bridge in loop II of long neurotoxins does not
affect the toxin activity. Nevertheless, cleavage of the additional
disulphide bridge in loop II can disrupt the positively charged
cluster at the tip of loop II. Changes in loop II conformation will
affect the binding of the long neurotoxin to the target receptor
resulting the loss of neurotoxicity (Peng et al., 1997).
Long and short neurotoxins show sequence homology and
similar structure. Previous studies show that many residues
located at the tip of loop II are conserved in both short and
long neurotoxins. It is consisting of the long central β-sheets
forming three loops and globular core. From the studies of
α-bungarotoxin and α-cobratoxin, the least conserved regions
of the long neurotoxin are the C-terminal and the first loop
(Walkinshaw et al., 1980; Juan et al., 1999; Dutertre et al., 2017).
However, significant differences between long-chain neurotoxin
and short chain neurotoxin are indicated by the immunological
reactivity. Many of the residues involved in the antibody-long
neurotoxins binding are located in loop II, loop III, and in the C-
terminal, while in short neurotoxins the antibody’s epitopemakes
interactions with the loop I and loop II (Engmark et al., 2016).
THERAPEUTIC IMPLICATIONS
Treating Snake Envenomation
Animal-derived antivenoms are considered the only specific
therapy available for treating snakebite envenoming (Maduwage
and Isbister, 2014; Slagboom et al., 2017; Ainsworth et al.,
2018). These consist of polyclonal immunoglobulins, such as
intact IgGs or F(ab’)2, or Fab fragments (Ouyang et al., 1990;
Maduwage and Isbister, 2014; Roncolato et al., 2015), derived
from hyperimmune animal serum/plasma (typically horse or
sheep). When used rapidly and appropriately, they are capable of
neutralizing life-threatening systemic envenoming, for example
pathologies such as venom-induced coagulopathy, hemorrhage,
neurotoxic effects, and/or hypotensive shock (Warrell, 1992;
Calvete et al., 2009;Maduwage and Isbister, 2014; Slagboom et al.,
2017; Ainsworth et al., 2018).
Antivenoms can be classified as monovalent or polyvalent
depending on the immunogen used during production.
Monovalent antivenoms are produced by immunizing animals
with venom from a single snake species, whereas polyvalent
antivenoms contain antibodies produced from a cocktail of
venoms of several medically relevant snakes from a particular
geographical region. Polyvalent antivenoms are therefore
designed to address the limited paraspecific cross-reactivity
of monovalent antivenoms by stimulating the production of
antibodies against diverse venom toxins found in different snake
species, and to avoid issues relating to the wrong antivenom being
given due to a lack of existing snakebite diagnostic tools (O’leary
and Isbister, 2009; Abubakar et al., 2010). However, polyvalent
therapies come with disadvantages—larger therapeutic dose are
required to effect cure, potentially resulting in an increased risk
of adverse reactions, and in turn increasing cost to impoverished
snakebite victims (Hoogenboom, 2005; O’leary and Isbister,
2009; Deshpande et al., 2013; Roncolato et al., 2015).
Variation in venom constituents therefore causes a great
challenge for the development of broadly effective snakebite
therapeutics. The diversity of toxins found in the venom of
any one species represents considerable complexity, which is
further enhanced when trying to neutralize the venom ofmultiple
species, particularly given variations in the immunogenicity of
the multi-functional toxins described in this review. Antivenom
efficacy is therefore, typically limited to those species whose
venoms were used as immunogens and, in a number of cases,
closely-related snake species that share sufficient toxin overlap for
the generated antibodies to recognize and neutralize the key toxic
components (Casewell et al., 2010; Segura et al., 2010; Williams
et al., 2011; Ainsworth et al., 2018).
Because variation in venom composition is ubiquitous at every
level of snake taxonomy (e.g., interspecifically, intraspecifically,
and even ontogenically Chippaux et al., 1991; Gibbs et al., 2013;
Casewell et al., 2014; Durban et al., 2017; Ainsworth et al., 2018),
gaining an understanding of venom composition in medically
important snake species is valuable, and can inform predictions
of the likely paraspecific neutralizing capability of an antivenom,
and therefore the geographical applicability of a particular
therapeutic. Consequently, venom toxicity/pathology analyses
in combination with venom proteomics, antivenomics, and/or
immunological analyses have been integrated to investigate the
paraspecificity of antivenoms (Calvete et al., 2009; Madrigal
et al., 2012; Pla et al., 2013; Tan et al., 2015). Such studies
have revealed surprising cross-reactivity of antivenoms against
distinct, non-targeted, snake species, such as: (i) the potential
utility of Asian antivenoms developed against terrestrial elapid
snakes at neutralizing the venom toxicity of potent sea snake
venoms (Tan et al., 2015), (ii) the seeming utility of African
polyvalent antivenom at neutralizing the venom of a genus of
elapid snakes not including in the immunizingmixture (Whiteley
et al., 2019), and (iii) the potential for saw-scaled viper antivenom
to be used as an alternative treatment for bites by the boomslang
(Dispholidus typus) in regions where the appropriate species-
specific antivenom is unavailable or unaffordable (Ainsworth
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et al., 2018). The later of these studies demonstrated cross-
neutralization between distinct snake lineages (e.g., viper and
colubrid), and this surprising finding was ultimately informed by
venom comparisons indicating that these snakes had converged
upon similar toxin compositions. Thus, detailed knowledge of
venom composition can greatly inform studies assessing the
geographical utility of antivenoms.
The application of “venomic” (e.g., transcriptomic,
proteomic) approaches to characterize venom composition
have revealed that many abundant venom proteins belong to
only a few major families of toxins, which despite their diversity,
often share antigenic determinants (Calvete et al., 2007, 2009;
Gutiérrez et al., 2009). Such studies have stimulated much
research into the development of novel therapeutic approaches
to tackle snakebite. These include the use of monoclonal
antibody technologies to target key pathogenic toxins found
in certain snake species (Laustsen et al., 2018; Silva et al.,
2018), pathology rather than geographically-focused approaches
to neutralizing venom toxins (Ainsworth et al., 2018), and
the use of small molecule inhibitors designed to generically
target specific toxin classes (Arias et al., 2017; Bryan-Quiros
et al., 2019). The priority targets for these “next generation”
snakebite therapeutics are the multifunctional toxins described
herein (PLA2s, SVMP, SVSP, 3FTX) because of the major
pathologies that they cause in snakebite victims. It is anticipated
that in the future these new therapeutics may offer superior
specificities, neutralizing capabilities, affordability and safety
over conventional antivenoms. However, the translation of their
early research promise into the mainstay of future snakebite
treatments will ultimately rely on further research on the
toxins that they are designed to neutralize. Specifically, the
selection, testing and optimization of new tools to combat
snake envenoming is reliant upon the characterization of key
pathogenic, and often multifunctional, toxins found in the
venom of a diverse array of medically important snake species.
Snake Toxins as Therapeutics, Cosmetics
and in Diagnostics
The first drug derived from animal venoms approved by the
FDA is captopril, a potent inhibitor of the angiotensin converting
enzyme (sACE) used to treat hypertension and congestive heart
failure (Cushman et al., 1977; Cushman and Ondetti, 1999).
Captopril was derived from proline-rich oligopeptides from
the venom of the Brazilian snake Bothrops jararaca (Ferreira
et al., 1970; Gavras et al., 1974). This milestone in translational
science in the late 70’s revealed the exceptional potential of snake
venoms, and possibly other animal venoms such as from spider
and cone snails, as an exquisite source of bioactive molecules
with applications in drug development. More recently, an anti-
platelet drug derived from the venom of the southeastern pygmy
rattlesnake Sistrurus miliarius barbouri was commercialized as
Integrillin by Millenium Pharmaceuticals, and is used to prevent
acute cardiac ischemia (Lauer et al., 2001). Furthermore, a
group of snake α-neurotoxins named waglerins from the viper
Tropidolaemus wagleri (Schmidt and Weinstein, 1995; Debono
et al., 2017) was used in the development of anti-wrinkle
cosmetics by Pentapharm Ltd., a Swiss-based chemical company.
The resulting product is now commercialized as Syn-AKE. The
same company commercialized Defibrase R©, a SVSP purified
from Bothrops moojeni, for use in acute cerebral infarction,
angina pectoris and sudden deafness, and Haemocoagulase,
purified from Bothrops atrox, for the treatment of hemorrhages
of various origins.
Snake toxins have been applied with great success in
diagnostics. For example, the Textarin: Ecarin test is commonly
used to detect Lupus Anticoagulant (LA) (Triplett et al., 1993),
and is composed by a SVSP from the venom of the Australian
Eastern brown snake Pseudonaja textilis (Textarin) (Stocker et al.,
1994), and a SVMP from the venom of the saw-scaled viper
Echis carinatus (Ecarin) (Stocker et al., 1986). Snake toxins
also have the potential to become novel painkillers. The toxin
crotalphine, from the venom of Crotalus durissus, is a 14 residues
peptide able to induce analgesia throughmodulation of κ-opioids
receptors and TRPV1 channels (Gutierrez et al., 2008; Konno
et al., 2008; Bressan et al., 2016), while mambalgin, a 3FTX
from Dendroaspis polylepis, induces analgesia by inhibiting ASIC
channels (Diochot et al., 2012). Other 3FTXs have been applied
in studies of novel treatments for blood pressure disorders
(MTα), blood coagulation disorders (KT-6.9), diabetes type-2
(cardiotoxin 1) and infertility (actiflagelin) (Utkin, 2019). These
findings, alongside current research into venom toxins, suggest
an exciting future for the use of snake venoms in the field of
drug discovery.
CONCLUSIONS
Snake venoms are amongst the most fascinating animal
venoms regarding their complexity, evolution, and therapeutic
applicability. They also offer one of the most challenging drugs
targets due to the variable toxin compositions injected following
snakebite. The multifunctional approach adopted by the major
components of their venoms, by using multidomain proteins
and peptides with promiscuous folds (e.g., three-finger fold), as
well as their diversity of toxic effects, are unique and yet to be
identified in other animal venoms at such level of complexity.
Gaining a better understanding of the evolution, structure-
activity relationships and pathological mechanisms of these
toxins is essential to develop better snakebite therapies and
novel drugs.
Recent developments in genomics, proteomics and bioactivity
assays, as well as in the understanding of human physiology
in health and disease, are enhancing the quality and speed
of research into snake venoms. We hope to improve the
therapies used to neutralize the toxic effects of PLA2s, SVMPs,
SVSPs and 3FTXs, and to develop drugs as new antidotes
for a broad-spectrum of snake venoms that could also be
effective in preventing the described inflammatory reactions
and pain induced by snakebite. Finally, a diversity of biological
functions in snake venoms is yet to be explored, including
their inflammatory properties and their intriguing interactions
with sensory neurons and other compartments of the nervous
system, which will certainly lead to the elucidation of new
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biological functions and the development of useful research tools,
diagnostics and therapeutics.
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